DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
|
|
- Noel Bradley
- 5 years ago
- Views:
Transcription
1 DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this photo and/or video. If you don t want your photo taken, please let us know. Thank you! ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
2 The last C.difficile presentation (at least for a few months) JESSICA THOMPSON, PHARMD, BCPS AQ- ID INFECTIOUS DISEASES PHARMACY CLINICAL SPECIALIST RENOWN HEALTH
3
4 Objectives Discuss the highlights and major differences between the 2010 and 2017 IDSA/SHEA C.difficile guidelines Slides refer to adult recommendations unless otherwise specificed
5 Diagnosis Preferred population for testing: Unexplained and new-onset 3 unformed stools in 24 hour Clinicians can improve laboratory test relevance by only testing patients likely to have C.difficile disease Suggestions: Do not routinely test stool from a patient who has received a laxative in the preceding 48 hours Develop, implement, and enforce stool rejection criteria
6 Testing In summary: Most facilities If you are unable optimize testing and/or rejection criteria do not use PCR alone for diagnosis
7 Repeat testing Test of cure: 60% of patients may remain positive Test for recurrence (i.e. recurrence of symptoms following successful treatment and diarrhea cessation): Use toxin detection, not NAAT (eg. PCR)
8 Implement antimicrobial stewardship Minimize Minimize the Restrict frequency and number of fluoroquinolones, duration of high- antibiotic agents clindamycins, and risk antibiotics prescribed cephalosporins
9 Treatment Discontinue therapy with the inciting antibiotic agent(s) as soon as possible, as this may influence the risk of recurrence Clinical Definition Recommended Treatment Initial episode, non-severe to severe Vancomycin 125 mg PO q6h x 10 days OR Fidaxomicin 200 mg PO BID x 10 days Initial episode, fulminant (hypotension, shock, ileus, megacolon) Vancomycin 500 mg PO/NG q6h PLUS Metronidazole 500 mg IV q8h especially if ileus is present If ileus also add Vancomycin 500 mg retention enema q6h May extend duration to 14 days if there is delayed treatment response
10 Surgery No defined criteria for surgical consultation or intervention Type of surgical intervention Subtotal colectomy with preservation of rectum OR Diverting loop ileostomy with colonic lavage followed by antegrade vancomycin flushes
11 Treatment of recurrence Clinical Definition First recurrence After initial treatment course of metronidazole After initial treatment course of vancomycin Second or subsequent recurrence Recommended Treatment Vancomycin 125 mg PO q6h x 10 days Vancomycin prolonged tapered and pulsed regimen OR Fidaxomicin 200 mg PO BID x 10 days Any one of the following: Vancomycin in a tapered and pulsed regimen Vancomycin followed by rifaximin chaser Fidaxomicin x 10 days Third CDI episode: Fecal microbiota transplant
12 Metronidazole Should only be used in the following scenarios Resource-limited settings in non-severe infections As IV for combination therapy in fulminant C.difficile Irreversible neurotoxicity associated with repeated or prolonged use Not recommended for treatment of recurrence in adults
13 Pediatric considerations Testing 2 years: Do not routinely test > 2 years: Test if prolonged or worsening diarrhea AND risk factors or relevant exposures Treatment
14 Summary Test the right patient Implement stool rejection criteria Don t use PCR alone *if unable to implement above measures Antimicrobial stewardship No oral metronidazole *except in pediatric patients Pulse/taper vancomycin for 2 nd occurrence FMT for 3 rd occurrence
15 Questions?
Clostridium difficile Infection (CDI) Management Guideline
Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for
More informationStony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics
Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection
More informationClostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate
Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium
More informationClostridium difficile Infection: Diagnosis and Management
Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,
More informationENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More informationClostridium difficile Infection (CDI)
18.09.10 월요집담회 Clostridium difficile Infection (CDI) R4 송주혜 Clostridium difficile infection (CDI) Anaerobic gram (+), spore-forming, toxin(tcda&tcdb)-producing bacillus Transmitted among humans through
More information9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)
Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In
More informationUpdated Clostridium difficile Treatment Guidelines
Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning
More informationClostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018
Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Disclosures None Objectives Highlight important changes in the management of Clostridium difficile
More informationClostridium difficile Infection (CDI) Guideline
Clostridium difficile Infection (CDI) Guideline Site Applicability All VCH PHC acute care and residential sites. Practice Level Physicians basic skill Pharmacists basic skill Nurses (RN, LPN, RPN) basic
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationDivision of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013
Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection
More informationLiterature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationResponders as percent of overall members in each category: Region: New England 50 (57% of 87 members) 46 (57% of 81 members) 21 (55% of 38 members)
Infectious Diseases Society of America Emerging Infections Network Report for Query: Recurrent C. difficile Infections (CDI) Overall response rate: 621/1212 (51.2%) physicians responded from 09/26/12 to
More informationOngoing Developments in Management of Clostridium difficile Infection
Ongoing Developments in Management of Clostridium difficile Infection Infectious Diseases Spring Symposium Creighton University School of Medicine April 28, 2018, Omaha, NB Stuart Johnson, MD Loyola U.
More informationModern approach to Clostridium Difficile Infection
Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research
More informationDISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit
GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which
More informationClostridium difficile: Can you smell the new updates?
Clostridium difficile: Can you smell the new updates? Sunish Shah, Pharm.D. PGY-2 Infectious Disease Pharmacy Resident Yale-New Haven Hospital sshah1741@mail.usciences.edu Learning objectives Recognize
More informationCase 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?
Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool
More informationACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections Christina M. Surawicz, MD 1, Lawrence J. Brandt, MD 2, David G. Binion, MD 3, Ashwin N. Ananthakrishnan,
More informationBezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital
Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile Janel Liane Cala, RPh Medical Center Hospital Objectives Review pathophysiology, risk factors, prevention, and treatment options of
More informationClostridium difficile Infection (CDI) Guideline Update:
Clostridium difficile Infection (CDI) Guideline Update: Understanding the Data Behind the Recommendations Erik R. Dubberke, MD, MSPH A Webinar for HealthTrust Members Professor of Medicine September 24,
More informationA Pharmacist Perspective
Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed
More informationWhat s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington
What s New for Clostridium difficile 2013 John Lynch MD MPH Harborview Medical Center University of Washington Pathogenic Mechanisms of Diarrhea Toxins: Preformed: S aureus, C perfringens, B cereus Formed
More informationTerapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco
Terapia dell infezione da Clostridium difficile Massimo Coen I Div Mal Inf AO L Sacco Disease Severity Mild CDI 3 5 BM/day WBC 15,000/mm 3 Defining CDI Disease Severity Mild abdominal pain due to CDI Moderate
More informationClostridium Difficile colitismore
Clostridium Difficile colitismore virulent than ever ECHO- February 18, 2016 Charles Krasner, M.D. UNR School of Medicine Sierra NV Veterans Affairs Hospital Growing problem of pseudomembranous colitis
More informationEDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationDisclosure. Objectives. Assessment Questions. History. Clinical Case 2/27/2015. Clostridium difficile update and new therapies
Disclosure Clostridium difficile update and new therapies Corey Frederick, PharmD PGY-2 Pharmacy Resident, Infectious Diseases Jackson Memorial Hospital Miami, Florida I do not have a vested interest in
More informationCLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System
CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J
More informationUpdate on Clostridium difficile infection.
Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible
More informationTreatment of Clostridium Difficile Infection in Community Teaching Hospital: A Retrospective Study
International Journal of Infectious Diseases and Therapy 2018; 3(3): 52-61 http://www.sciencepublishinggroup.com/j/ijidt doi: 10.11648/j.ijidt.20180303.12 ISSN: 2578-9651 (Print); ISSN: 2578-966X (Online)
More informationClostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011
Clostridium Difficile Associated Disease Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Introduction Which of the following is more common in community hospitals in the Southeast
More informationCLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT. Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates
CLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates Learning Objectives Recognize patients who are highest risk for C. diff infections
More informationLong-Term Care Updates
Long-Term Care Updates April 2018 By Austin Smith, PharmD Candidate and Lindsay Slowiczek, PharmD is the most common healthcare-acquired infection (HAI) in the United States. 1,2 A 2014 prevalence survey
More informationManaging Clostridium Difficile: An Old Bug With
932 The Red Section see related editorial on page x Managing Clostridium Difficile: An Old Bug With New Tricks Stephen M. Vindigni, MD, MPH 1,2 and Christina M. Surawicz, MD 1 Am J Gastroenterol (2018)
More informationDrug Class Update with New Drug Evaluation: Medications for Clostridium difficile Infection
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDiagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review
Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationClostridium difficile
Clostridium difficile Alex Aspinall MD, PhD, FRCPC Clinical Assistant Professor, University of Calgary Division of Gastroenterology and Hepatology, South Health Campus www.seacourses.com 1 Learning Points
More informationNursing Infectious Diseases Topics. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle
Nursing Infectious Diseases Topics David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Clostridium difficile Free Access Via Web Source: Cohen SH,
More informationNote: Active Table of Contents Click to follow link
Clostridium difficile Infection: Prevention, Diagnosis and Treatment Adult/Pediatric Inpatient/Ambulatory/Emergency Department Clinical Practice Guideline Note: Active Table of Contents Click to follow
More informationC. difficile and ASP Guidelines and Best Practices. Belinda Ostrowsky, MD, MPH, FSHEA, FIDSA February 27 and 28, 2018
C. difficile and ASP Guidelines and Best Practices Belinda Ostrowsky, MD, MPH, FSHEA, FIDSA February 27 and 28, 2018 Disclosure I have no financial disclosures I have made a recent transition from Montefiore
More informationJourney to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer
Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical
More informationC. Difficile Testing Protocol
C. Difficile Testing Protocol Caroline Donovan, RN, BSN, ONC- Infection Control Practitioner Abegail Pangan, RN, MSN, CIC- Infection Control Practitioner U.S. NEWS & WORLD REPORT 2017 2018 RANKINGS Acute
More informationLearning Objectives. A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials. Fidaxomicin vs. Vancomycin. Outline 1/3/2012
Learning Objectives A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials Amy E. Lodolce, PharmD, BCPS Assistant Director, Drug Information Group UIC College of Pharmacy Describe the methods and
More informationAnnex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening
Annex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening There s an updated Annex C Annex C is an extension to the PIDAC Infection Prevention
More informationClostridiodes Difficile Colitis: Update on Guidelines. Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018
Clostridiodes Difficile Colitis: Update on Guidelines Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018 Outline Overview of CDI Diagnosis of C Difficile- updates Infection Prevention
More informationClostridium difficile in Adults
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2018 ~ Resource #340405 Clostridium difficile in Adults Clostridium difficile (C. difficile)
More informationManagement of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery
Management of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery Rahul Narang, MD Colon and Rectal Surgery Assistant Professor of Surgery No Disclosure Clostridium Difficile Colitis: Treatments,
More informationUpdates to pharmacological management in the prevention of recurrent Clostridium difficile
Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing
More informationClostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure
Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Brian S. Zuckerbraun, MD, FACS Henry T. Bahnson Professor of Surgery University of Pittsburgh Chief, Trauma
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationThe Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH
The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick
More informationClostridium difficile infections: Drug treatment re-evaluated
Clostridium difficile infections: Drug treatment re-evaluated Kimberly D. Leuthner, PharmD University Medical Center of Southern Nevada August 11, 2016 Random Fact: The human body has 10 13 human cells
More informationPatient presentation
Update: Clostridium difficile Colitis David H. Kerman, MD Assistant Professor of Clinical Medicine Director, Fellowship Program Division of Gastroenterology University of Miami Miller School of Medicine
More informationAll POOPed out: fecal microbiota transplant in C. difficile
All POOPed out: fecal microbiota transplant in C. difficile SUSAN M. KELLIE, MD, MPH PROFESSOR OF INTERNAL MEDICINE DIVISION OF INFECTIOUS DISEASES UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE HOSPITAL
More informationClostridium difficile infections and fecal transplant
Objectives Clostridium difficile infections and fecal transplant Recognize patients at risk for C. difficile infection (CDI) Contrast diagnostic testing for CDI Describe treatment strategies for mild,
More informationIs FMT the answer? Challenging Cases in CDI. Ted Steiner, M.D. April 1, 2016
Is FMT the answer? Challenging Cases in CDI Ted Steiner, M.D. April 1, 2016 CONFLICT OF INTEREST DISCLOSURE SLIDE In the past 2 years I have been an employee of: In the past 2 years I have been a consultant
More informationClinical Infectious Diseases IDSA GUIDELINE
Clinical Infectious Diseases IDSA GUIDELINE Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and
More informationClostridioides difficile Infection: What s the BIG Stink?
Clostridioides difficile Infection: What s the BIG Stink? GLORIA MATHIS, RN, BSN, CIC 29 TH ANNUAL MEDICAL SURGICAL CONFERENCE APRIL 4, 2019 SAN FRANCISCO, CA I am sre my patient has C. diff. I cold smell
More informationAddressing Today s Challenging Bacterial Infections: Expert Views on Treatment Paradigms
Addressing Today s Challenging Bacterial Infections: Expert Views on Treatment Paradigms Symposium Outcomes Report Merck Grant ID: AAN-180403-047752 Overview Activity Description: This symposium provided
More informationUnderstanding C. diff. atomalliance.org/cdifftraining
Understanding C. diff atomalliance.org/cdifftraining This booklet is a printed guide of the online educational resource atomalliance.org/cdifftraining Target Audience Understanding C. diff This educational
More informationMarch 3, To: Hospitals, Long Term Care Facilities, and Local Health Departments
March 3, 2010 To: Hospitals, Long Term Care Facilities, and Local Health Departments From: NYSDOH Bureau of Healthcare Associated Infections HEALTH ADVISORY: GUIDANCE FOR PREVENTION AND CONTROL OF HEALTHCARE
More informationCDI The Impact. Disclosures. Acknowledgments. Objectives and Agenda. What s in the Name? 11/14/2012. Lets Talk Numbers
Disclosures No conflict of interest to declare Acknowledgments Objectives and Agenda Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Guidelines
More informationFecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond
Fecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond Amir Patel, MD Assistant Professor of Medicine Froedtert Hospital and the Medical College of Wisconsin I have
More informationC. difficile Infection: How it all comes out
C. difficile Infection: How it all comes out Larry Danziger, Pharm.D. Professor of Pharmacy and Medicine College of Pharmacy University of Illinois at Chicago The speaker has no conflicts to disclose.
More informationClostridium difficile
Clostridium difficile Sarah Doernberg, MD, MAS Assistant professor and Medical Director of Antimicrobial Stewardship Division of Infectious Diseases, UCSF 2.19,2018 Outline Brief background and epidemiology
More informationClostridium difficile
Clostridium difficile Sarah Doernberg, MD, MAS Assistant Professor, University of California, San Francisco Medical Director, Adult Antimicrobial Stewardship Disclosures: Consultant for Actelion, prior
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Juul FE, Garborg K, Bretthauer M, et al. Fecal microbiota transplantation
More informationDuodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience
Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience Benoit Guery Unité des Maladies Infectieuses CHRU - Faculté de Médecine Lille Conflicts of interest Conferences,
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact ame and Job Title (author) Directorate & Speciality Date of submission December 2015 Date on which guideline
More informationC. DIFFICILE UPDATE. Heather Bell, DO Infectious Diseases Physician
C. DIFFICILE UPDATE Heather Bell, DO Infectious Diseases Physician None to report DISCLOSURE Case review Review IDSA CDI guidelines discuss changes Questions Testing recommendations Treatment recommendations
More informationInter-hospital Geriatrics Meeting August 2014 The Watery Curse
Inter-hospital Geriatrics Meeting August 2014 The Watery Curse Speaker: Dr. KK Yam (QMH) Supervisor: Dr. Patrick Chiu Patient s history F/95 Lives with daughter & maid ADL partially dependent. Walks with
More informationZinplava. (bezlotoxumab) New Product Slideshow
Zinplava (bezlotoxumab) New Product Slideshow Introduction Brand name: Zinplava Generic name: Bezlotoxumab Pharmacological class: Human IgG1 monoclonal antibody Strength and Formulation: 25mg/mL; solution
More information! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery
Case MQ is a 44 year old woman that I first saw in Sept 2006 UPDATE ON CLOSTRIDIUM DIFFICILE DISEASE Richard A. Jacobs, M.D.,PhD In MVA in Jan 2003 requiring spinal surgery Subsequently developed fecal
More information7/30/2018 C. DIFFICILE UPDATE DISCLOSURE OUTLINE. Heather Bell, DO Infectious Diseases Physician. None to report
C. DIFFICILE UPDATE Heather Bell, DO Infectious Diseases Physician None to report DISCLOSURE Case review Review IDSA CDI guidelines discuss changes Testing recommendations Treatment recommendations Isolation
More informationC.Difficile Associated Diarrhea Overview & Management. Sajal Chopra Pharm D. Candidate
C.Difficile Associated Diarrhea Overview & Management Sajal Chopra Pharm D. Candidate Learning Objectives 1. Recognize the increasing incidence of C.difficile associated diarrhea (CDAD) and its risk factors
More informationPage 1 of 10 PRESENTATION ASSESSMENT INTERVENTION. For severe and severe/ complicated disease criteria and treatment, see Page 2
PRESENTATION ASSESSMENT INTERVENTION Patient with 3 unformed stools in last 24 hours 1 Assessment and Management of Has patient been taking laxatives over the past 24-48 hours 2? Stop laxative and reassess
More informationClostridium Difficile Infection in Adults Treatment and Prevention
Clostridium Difficile Infection in Adults Treatment and Prevention Definition: Clostridium Difficile colonizes the human intestinal tract after the normal gut flora has been altered by antibiotic therapy
More informationClostridium difficile (C difficile)
Patient Knowledge and Attitudes About for Clostridium difficile Infection Colin Goodman, MD; Nicholas O Rourke, PharmD; Carla Amundson, MA; and Dimitri Drekonja, MD, MS In a survey of patients with Clostridium
More informationClostridium difficile Not Just a Hospital Problem Anymore. Objectives. The C. difficile Carrier State. Conflicts of Interest Disclosure
Conflicts of Interest Disclosure Daniel Leffler, MD, MS I disclose the following financial relationships with commercial entities that produce health carerelated products or services relevant to the content
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Fecal Microbiota Transplant MP-066-MD-PA Medical Management Provider Notice Date: 10/15/2018; 01/15/2018 Issue Date: 11/15/2018;
More informationClostridium difficile infection surveillance: Applying the case definition
Clostridium difficile infection surveillance: Applying the case definition PICNet Conference March 3 rd 2016 Presented by: Tara Leigh Donovan, MSc Managing Consultant (Former Epidemiologist) 1 Disclaimer
More informationLoyola s C diff Journey
Loyola s C diff Journey Kevin Smith, MD Associate Chief Medical Officer, Quality & Safety Aziz Ansari, DO Associate Chief Medical Officer, Clinical Optimization/Revenue Integrity Background Loyola Medicine
More informationClostridium difficile infections Crappy Options
Clostridium difficile infections Crappy Options Alexandru Petre David MD Infectious Diseases April 21, 2015 Objectives Microbiology Epidemiology Who is at risk? Pathogenesis Diagnosis Treatment Historical
More informationC. difficile: When to Do Fecal Microbiota Transplant (FMT)
C. difficile: When to Do Fecal Microbiota Transplant (FMT) Lawrence J. Brandt, MD, MACG Emeritus Chief, Gastroenterology Montefiore Medical Center Professor of Medicine and Surgery Albert Einstein College
More informationAn Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53
An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media formats
More informationarguably the greatest risk to human health comes in the form of antibiotic-resistant bacteria. We live in a bacterial world where we will never be
arguably the greatest risk to human health comes in the form of antibiotic-resistant bacteria. We live in a bacterial world where we will never be able to stay ahead of the mutation curve. A test of our
More informationClinical Primer: Position Statement for Fecal Microbiota Transplantation Administration for Recurrent Clostridium difficile Infection
Clinical Primer: Position Statement for Fecal Microbiota Transplantation Administration for Recurrent Clostridium difficile Infection Zain Kassam MD, MPH, FRCPC Chief Medical Officer, OpenBiome Disclaimer
More informationEPIDEMIOLOGY AND PREVENTION OF CLOSTRIDIUM DIFFICILE INFECTION (CDI)
EPIDEMIOLOGY AND PREVENTION OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics & Epidemiology Associate Chief Medical Offer, UNC Health Care Medical
More informationA Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management
Infect Dis Ther (2016) 5:207 230 DOI 10.1007/s40121-016-0122-1 REVIEW A Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management Csaba Fehér. Josep
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Fecal Microbiota Transplant MP-066-MD-DE Medical Management Provider Notice Date: 10/15/2018; 04/15/2018 Issue Date: 11/15/2018;
More informationLos Angeles County Department of Public Health: Your Partner in CDI Prevention
Los Angeles County Department of Public Health: Your Partner in CDI Prevention Dawn Terashita, MD, MPH Acute Communicable Disease Control Los Angeles County Department of Public Health dterashita@ph.lacounty.gov
More informationHistorical Perspective
The Diagnosis of C. difficile Infections: Does Molecular Make it More or Less difficile? Stephen M. Brecher Ph.D. VA Boston Health Care System BU School of Medicine The opinions expressed in this presentation
More informationGUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS
GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS Version 3.0 Date ratified May 2008 Review date May 2010 Ratified by NUH Antibiotic Guidelines Committee NUH Drugs and Therapeutics
More informationNicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma. L infezione da C difficile grave o complicata
Nicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma L infezione da C difficile grave o complicata Bagdasarian N et al. JAMA 2015; 313: 398-408 European Society
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationVirtual Lectures Planning Committee Disclosure Summary
Mayo Medical Laboratories Virtual Lectures 2014 MFMER Virtual Lectures Planning Committee Disclosure Summary As a provider accredited by ACCME, College of Medicine, Mayo Clinic (Mayo School of CPD) must
More informationClostridium difficile Diagnostic and Clinical Challenges
Papers in Press. Published December 11, 2015 as doi:10.1373/clinchem.2015.243717 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2015.243717 Clinical Chemistry 62:2 000 000
More information